Definitive Contract HHSN261201300024C

This is a federal contract award from the National Cancer Institute, a civilian agency, to Hemoshear Therapeutics, LLC, a small business. The contract, valued at $1,985,657.32, is for SBIR Phase II work titled "Validation of the HemoShear Tumor Microenvironment System for Drug Discovery and Development." The contract is a Cost Plus Fixed Fee Definitive Contract and was awarded on September 21, 2015, with an ultimate completion date of April 30, 2019. The contract was set aside for...

This is a $1,646,541.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Glycan Therapeutics Corporation, a small disadvantaged business. The contract is for the chemoenzymatic synthesis of heparin sulfate under the Small Business Innovation Research (SBIR) Phase II program. The work is focused on developing synthetic heparan sulfate...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of &quot;Targeted Nanoparticle Treatment for Breast Cancer Stem Cells.&quot; This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This is a delivery order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services (HHS), to FEI.com, Inc. (doing business as FEI COM Inc.), a minority-owned, for-profit IT services company. The $315,758.25 contract, awarded under the Chief Information Officer - Solutions and Partners 3, Small Business (CIO-SP3 SB) governmentwide acquisition contract, is for operation, maintenance, and enhancement support of the HHS Small Business...

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (DHHS), to Theranano LLC, a small disadvantaged, woman-owned business. The $300,000 fixed-price contract is for research on the sustained delivery of PARP inhibitors for cancer chemoprevention. This SBIR contract was issued under the DHHS/NIH/CDC SBIR Contract Solicitation PHS 2018-1, which sought proposals from small...